Testing a new Herceptin shot in healthy men
This trial tests a new version of the breast cancer drug Herceptin (called Bmab3000) given as a single shot under the skin. It looks at how the drug moves through the body, its safety, and how the immune system responds, in healthy volunteers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a healthy man between 18 and 65 years old.
- Your weight is between 110 and 220 pounds, and your BMI is between 18.5 and 30.
- Your heart function (LVEF) is at least 55%.
- You agree to use effective birth control during the study and for 3 months after.
- You have not taken any prescription or over-the-counter medications recently (within 14–30 days).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new antibody-based drugs (trastuzumab rezetecan and trastuzumab deruxtecan) designed to treat advanced breast cancer that has spread or cannot be removed with surgery. These drugs target HER2, a protein found on certain cancer cells, and may help patients whose cancer has progressed after previous treatment with trastuzumab and chemotherapy.
This trial tests a form of the drug trastuzumab deruxtecan that is given as a shot under the skin for people with certain metastatic solid tumors, including breast cancer and non-small cell lung cancer with HER2 changes. It aims to see how well the shot works and if it is safe.
This trial tests a combination of targeted therapies (trastuzumab and pertuzumab) with chemotherapy (docetaxel) and an experimental drug (QL1706) given before surgery to shrink early or locally advanced HER2-positive breast cancer. It aims to see if this approach improves outcomes before definitive surgery.
This trial tests a combination of two drugs (KN026 and HB1801) given after surgery to prevent breast cancer from coming back in people with HER2-positive breast cancer that had spread to lymph nodes. It aims to improve cure rates with a targeted approach.
This trial tests a new combination of drugs for people with HER2-positive early breast cancer whose tumors did not respond well to the first round of standard targeted therapy plus chemo. The goal is to see if switching to trastuzumab-rezetecan plus pertuzumab or a different chemo combo (nab-paclitaxel, carboplatin, trastuzumab, and pyrotinib) can shrink the tumor before surgery.
This trial tests a new drug called JSKN003 against standard HER2-targeted therapy (trastuzumab plus pertuzumab and docetaxel) for HER2-positive breast cancer that has spread. The goal is to see if the new drug works better or causes fewer side effects.
Hear when a new Healthy Male Participants trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.